TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Antiviral response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Embryos number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pregnancies rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: HER2-HER3 dimer expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HER2 over-expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hierarchal Composite Outcome of Patient-Important Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Modified Rankin Scale (mRS) categorical analysis
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total Number of Relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Sustained Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD Symptom Scale-Interview for DSM-5 (PSS-I-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sit-to-stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Permanent Discontinuation of IMP
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormal Clinically Significant Vital Signs Per Investigator's Interpretation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Results Per Investigator's Interpretation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Exceeding Maximum Daily Dose of 1200 mg
Endpoint domain: Adverse events/effects
Primary endpoint: rate of complete remission (CR) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day 28 mortality and/or organ failure
Endpoint domain: Mortality/survival
Primary endpoint: Complete response rate (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: de novo lipogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Variation in direct and indirect medical costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Viral clearance at day 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms clearance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin resistance index: triglyceride to glucose ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin resistance index: triglyceride to HDL ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Motor Evoked Potential (MEP) Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Treadmill exercise time increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BCG-induced cellular immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Sustained Virological Response (SVR) 24 Weeks After End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hemoglobin Level at Week 12 of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ICU, hospital and 90-day mortality
Endpoint domain: Mortality/survival
Primary endpoint: Ventilator-free days and alive at day 28
Endpoint domain: Mortality/survival
Primary endpoint: Change in Quality of Life in Neurologic Disorders (NeuroQoL) Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Vertical Load Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Foot Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in running cadence (steps per minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficult bag mask ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Liver related morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Echocardiographic signs of rheumatic heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge of semen collection methods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of Leuvectin
Endpoint domain: Adverse events/effects
Primary endpoint: Electromyography measurement - Root Mean Square (RMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Fiberoptic Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total Number of Times Mobilized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device related serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Non-fatal myocardial re-infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Viscoelastic Properties Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Achieving a ≥ 50% Improvement in Total Symptom Score-Cytokine (TSS-C)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neck-to-Arm TDC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sub-Mental-to-Arm TDC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in exercise activity over 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Measuring trends in Blood Pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measuring trends in weight measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of HAMD-17 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical Site Occurrence (SSO) including Surgical Site Infection (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the glucose infusion rate-time curve of insulin aspart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Faecal bile acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reluxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient-reported functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postprandial serum amino acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patients performance on neuropsychological tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivities of 18F-fluorocholine PET/CT and 99mTc sestamibi scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificities of 18F-fluorocholine PET/CT and 99mTc sestamibi scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracies of 18F-fluorocholine PET/CT and 99mTc sestamibi scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tinnitus handicap inventory score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ongoing pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Virologic Response at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Pharmacokinetics (PK) of DEB025 and EDP239: Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax, ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of intraoperative hypovolemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Device- and Surgical-Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of Esophageal Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastroduodenal ulcers at final visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ICH recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 3-month outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Capillary glycaemia measures out of range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ordinal modified Rankin Scale (mRS) at 3 months after stroke onset
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Left Ventricular Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regional Left Ventricular Function (Infarct Zone Wall Motion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regional Left Ventricular Function (Border Zone Wall Motion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Grade 4-5 Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with HIV RNA levels < 50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional motor power outcome at 12 months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Mucosal Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Kaolin-activated Clotting Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: accuracy of prognosis prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality of the patients
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness of intervention in hypercholesterolemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adequate relief of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Walked on Six Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anxiety and depression levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Glycosylated Hemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Tear Break up Time (TBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change From Baseline in Dry Eye Symptom Scores (OSDI Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Hearing In Noise Test Score in Quiet (HINT-Q)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Related Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of clinical laboratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in eating disorders symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of binging and purging episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in food craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive symptoms measured by EPDS mean score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of the relationship
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in rest Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Ambulatorial Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: false discovery rate of exercise stress tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Echocardiography findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improved health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Children Who Received Early and Appropriate Treatment for Pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Children With Fever Who Received Coartem (Artemether-lumefantrine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Relief of dysphagia
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dose-normalized Cmax for Alisertib Oral Solution vs Powder in Capsule Formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-normalized AUClast for Alisertib Oral Solution vs Powder in Capsule Formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Toxicity Associated With Danazol Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Responses (Complete Response or Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chatoor feeding scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P.falciparum parasitaemia detected by PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of abnormal Thyroid Stimulating Hormone (TSH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of satiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of detecting Bcl2 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of detecting apoptosis in CTCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychosocial factors affecting daily lives
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentages of Subjects With RVNA Titer >= 0.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hemostasis in the 6 first hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hemostasis at the 24th hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Spontaneous hemorrhagic events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in estimated cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of educational achievement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of PML
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge on HIV prevention and transmission
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitude towards HIV/AIDS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: diagnostic performance for detection of additional cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total Bacteria Colony Forming Units (CFUs; Natural-log Transformed) with Tryptic Soy Agar (TSA) Plating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total Bacteria Colony Forming Units (CFUs; Natural-log Transformed) with MacConkey Agar Plating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total Bacteria Colony Forming Units (CFUs; Natural-log Transformed) with Phenylethyl Alcohol (PEA) Plating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline LENA scores in Adult Word Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline LENA scores in Conversational Turn Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline LENA scores in Child Vocalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary Risk Score (DRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Supplement use Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biochemical Assessment of serum folate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of days at work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Airway resistance and reactance (R5, X5, R-D5-20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Progression of the Calcium score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (≥10% Overall)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Achieved Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Home Practice
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Menstrual Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Local Control Rate (Absence of Local Progression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive Patient Health Questionnaire-2 (PHQ-2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive Generalized Anxiety Disorder-2 (GAD-2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive Pittsburgh Sleep Quality Index-Addendum for PTSD (PSQI-A)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Incidence of healthcare workers with SARS-CoV-2
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of ENT patients with SARS-CoV-2
Endpoint domain: Adverse events/effects
Primary endpoint: Development of SARS-CoV-2 antibodies among healthcare workers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: neurologic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: solid fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the plasma drug concentration - time curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologically confirmed cervical intraepithelial neoplasia grade 2 or worse (CIN2+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum velocity of pupil dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in stool frequency, measured by Bristol Stool Form (BSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in pain VAS value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Seroprotected Subjects Against Diphteria and Tetanus Toxoid Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-T Antibody Concentrations ≥ the Assay Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroconverted Subjects Against Influenza Antigens H1N1, H3N2, and B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: COPD assessment test (CAT) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depression in COPD patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients that survive at least 12 months
Endpoint domain: Mortality/survival